Cizzle Bio Inc. founder and CEO Bill Behnke moderated a high-profile panel at the 2025 Association for Value-Based Cancer ...

The drug, JSKN003, showed promising early efficacy in colorectal cancer patients in China in a Phase I/II trial.

Cancer treatment is no longer limited to standard protocols . The same drug, given in the same way, does not work for every ...

Guardant Health and Zephyr AI have partnered to advance the discovery of novel cancer biomarkers, as more precise tumour ...

Oncology-focused biotech company Guardant Health is partnering with AI drug development company Zephyr AI to combine AI and ...

Sometimes the unintended consequences of a treatment can seem worse than the disease. That's certainly the case for patients ...

The United States Prostate Cancer Biomarkers Market is projected to grow from $1.48 billion in 2024 to $3.54 billion by 2033, ...

Ipilimumab plus nivolumab improved PFS over nivolumab alone in MSI-H/dMMR mCRC, with no new safety concerns. The combination showed higher overall response rates and a favorable safety profile ...

Adelaide researchers have identified a promising new biomarker and treatment target for ovarian cancer that could markedly ...

Guardant Health (Nasdaq: GH), a leading precision oncology company, and Zephyr AI, a leader in precision medicine harnessing artificial intelligence to accelerate drug development, today announced a ...

Adding the antiangiogenic drug to standard care does not extend overall survival among patients with metastatic esophageal ...

Biomarker testing is ushering in a novel era of therapy personalisation for gastroesophageal and colorectal cancers, ...